Increased expression of HDAC1, 2 and 3 has been associated with poor outcome in gastric and ovarian cancer [36–38], while high HDAC8 levels correlate with advanced disease and poor survival in neuroblastoma [39, 40]. Here, HDAC8 is linked to ovarian cancer.